Compare PDS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | NVAX |
|---|---|---|
| Founded | 1951 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | PDS | NVAX |
|---|---|---|
| Price | $68.38 | $6.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $98.00 | $10.78 |
| AVG Volume (30 Days) | 76.5K | ★ 3.5M |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.98 | 2.07 |
| Revenue | ★ $1,316,232,437.00 | $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $23.04 | ★ $3.17 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $36.20 | $5.01 |
| 52 Week High | $71.77 | $11.55 |
| Indicator | PDS | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 39.00 |
| Support Level | $56.10 | $6.43 |
| Resistance Level | $71.77 | $6.84 |
| Average True Range (ATR) | 2.29 | 0.21 |
| MACD | 0.49 | 0.04 |
| Stochastic Oscillator | 77.87 | 23.95 |
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.